My research focuses in understanding the molecular mechanisms of neurodegeneration as well the development of fluid biomarkers for neurodegenerative diseases.

My main achievements have been: (1) Development of CSF sTREM2 as a marker of microglial activity in Alzheimer’s disease; (2) Description of the first post-translational modification specifically associated with FTLD-FUS, namely monomethylated arginine (MMA) FUS; (3) Tau propagation in mice model of early AD; (4) Demonstrate the early increase of blood biomarkers of Alzheimer diseases (i.e. p-tau, GFAP) in the preclinical stage of the disease. I have combined my clinical experience with a strenuous activity as a basic researcher, proven by my publications in high-impact journals, such as Nature Medicine, Science Translational Medicine, EMBO Molecular Medicine, Acta Neuropathologica, Lancet Neurology or Neuron.